Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …

Abstract Background Direct oral anticoagulants (DOACs) are widely used for the treatment of
venous thromboembolism (VTE) and for stroke prevention in atrial fibrillation (AF). However …

Essentials• The association of body weight and patient‐important outcomes remains
unknown.• Phase III randomized controlled trials of direct oral anticoagulants (DOACs) were …

Non–vitamin K antagonist anticoagulants (NOACs) have been used to prevent
thromboembolism in patients with atrial fibrillation (AF) and shown favorable clinical …

Objective There has been limited systematic evaluation of outcomes and drivers of
inappropriate non-vitamin K antagonist oral anticoagulants (NOACs) dosing among patients …

Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …

Background Although several meta‐analyses have examined the effects of off‐label
underdosing of nonvitamin K antagonist oral anticoagulants (NOACs) compared with their …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) are alternative to
vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation (AF) …

Methods We initially carried out a comprehensive search of databases from inception to
June 2023 for eligible studies exploring the efficacy and safety of various analogs of direct …

Background: Guidelines caution against the use of non–vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …